phosphonoacetic acid has been researched along with Cytomegalovirus in 56 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Clinical isolates of human cytomegalovirus (HCMV) were screened for susceptibility to ganciclovir by plaque-reduction assay and in situ ELISA." | 7.68 | A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. ( Lurain, NS; Tatarowicz, WA; Thompson, KD, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Investigations of mutants of human cytomegalovirus (CMV) that are resistant to foscarnet could shed light on mechanisms of selective drug action and features of drug resistance that may be clinically important." | 7.68 | Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. ( Coen, DM; Sullivan, V, 1991) |
| "The antiviral effect of ganciclovir and foscarnet encapsulated in liposomes was studied against cytomegalovirus in human embryonic lung fibroblast cells." | 7.68 | Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. ( Bakker-Woudenberg, IA; Lokerse, AF; ten Kate, M, 1990) |
| "Ganciclovir and foscarnet possess substantial activity against cytomegalovirus." | 7.68 | Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. ( Lane, HC; Manischewitz, JF; Quinnan, GV; Wittek, AE, 1990) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 7.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| "Eight independently derived mouse cytomegalovirus (MCMV) mutants resistant to acyclovir (ACV) were obtained by the sequential plating of wild-type virus in increasing concentrations of ACV." | 7.67 | Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir. ( Burns, WH; Sandford, GR; Saral, R; Simons, JW; Staal, SP; Wingard, JR, 1985) |
| "Mutants of the human cytomegalovirus (HCMV) that were 6- to 13-fold more resistant to phosphonoacetic acid than the wild-type HCMV (Towne) were isolated." | 7.67 | Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus. ( D'Aquila, RT; Summers, WC, 1987) |
| "The antiviral activity of trifluorothymidine (TFT) singly and in combination with other antiviral agents against human cytomegalovirus (HCMV) was evaluated by using an infectious center plaque reduction assay." | 7.66 | Inhibition of human cytomegalovirus by trifluorothymidine. ( Kelley, E; Spector, SA; Tyndall, M, 1983) |
| "A concomitant treatment of cytomegalovirus infections, such as cytomegalovirus retinitis, with phosphonoformate in patients with acquired immunodeficiency syndrome receiving 3'-azido-3'-deoxythymidine may be appropriate, and this combination may also be useful in controlling human immunodeficiency virus infection." | 5.28 | Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. ( Eriksson, BF; Schinazi, RF, 1989) |
| " The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated." | 5.26 | Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. ( Kelley, E; Spector, SA; Tyndall, M, 1982) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "Clinical isolates of human cytomegalovirus (HCMV) were screened for susceptibility to ganciclovir by plaque-reduction assay and in situ ELISA." | 3.68 | A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. ( Lurain, NS; Tatarowicz, WA; Thompson, KD, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Investigations of mutants of human cytomegalovirus (CMV) that are resistant to foscarnet could shed light on mechanisms of selective drug action and features of drug resistance that may be clinically important." | 3.68 | Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. ( Coen, DM; Sullivan, V, 1991) |
| "The antiviral effect of ganciclovir and foscarnet encapsulated in liposomes was studied against cytomegalovirus in human embryonic lung fibroblast cells." | 3.68 | Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. ( Bakker-Woudenberg, IA; Lokerse, AF; ten Kate, M, 1990) |
| "Ganciclovir and foscarnet possess substantial activity against cytomegalovirus." | 3.68 | Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. ( Lane, HC; Manischewitz, JF; Quinnan, GV; Wittek, AE, 1990) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 3.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| "Results presented here show that when cytomegalovirus (strain Colburn)-infected cells are treated with the DNA synthesis inhibitor hydroxyurea or phosphonoformate, one type of intranuclear capsid accumulates." | 3.67 | Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly. ( Gibson, W; Irmiere, A; Lee, JY, 1988) |
| "Eight independently derived mouse cytomegalovirus (MCMV) mutants resistant to acyclovir (ACV) were obtained by the sequential plating of wild-type virus in increasing concentrations of ACV." | 3.67 | Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir. ( Burns, WH; Sandford, GR; Saral, R; Simons, JW; Staal, SP; Wingard, JR, 1985) |
| "Mutants of the human cytomegalovirus (HCMV) that were 6- to 13-fold more resistant to phosphonoacetic acid than the wild-type HCMV (Towne) were isolated." | 3.67 | Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus. ( D'Aquila, RT; Summers, WC, 1987) |
| "Chromatin prepared from (14C)-thymidine pulse labelled cytomegalovirus-infected human fibroblasts 72 hours postinfection exhibited under appropriate conditions endogenous activity of (3H)-thymidine triphosphate incorporation which was relatively salt-resistant and phosphonoacetic acid-sensitive." | 3.66 | DNA synthesis in chromatin preparations from human fibroblasts infected by cytomegalovirus. ( Furukawa, T; Plotkin, S; Radsak, K, 1980) |
| "The antiviral activity of trifluorothymidine (TFT) singly and in combination with other antiviral agents against human cytomegalovirus (HCMV) was evaluated by using an infectious center plaque reduction assay." | 3.66 | Inhibition of human cytomegalovirus by trifluorothymidine. ( Kelley, E; Spector, SA; Tyndall, M, 1983) |
| " These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms." | 2.66 | Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| "A concomitant treatment of cytomegalovirus infections, such as cytomegalovirus retinitis, with phosphonoformate in patients with acquired immunodeficiency syndrome receiving 3'-azido-3'-deoxythymidine may be appropriate, and this combination may also be useful in controlling human immunodeficiency virus infection." | 1.28 | Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. ( Eriksson, BF; Schinazi, RF, 1989) |
| " The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated." | 1.26 | Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. ( Kelley, E; Spector, SA; Tyndall, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (58.93) | 18.7374 |
| 1990's | 22 (39.29) | 18.2507 |
| 2000's | 1 (1.79) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wahren, B | 7 |
| Robèrt, KH | 1 |
| Nordlund, S | 1 |
| Spector, SA | 2 |
| Tyndall, M | 2 |
| Kelley, E | 2 |
| Nishiyama, Y | 1 |
| Maeno, K | 1 |
| Yoshida, S | 1 |
| Oberg, B | 4 |
| Radsak, K | 4 |
| Schmitz, B | 1 |
| Furukawa, T | 1 |
| Plotkin, S | 1 |
| Weder, D | 2 |
| Mar, EC | 1 |
| Patel, PC | 1 |
| Huang, ES | 1 |
| Eriksson, B | 2 |
| Burns, WH | 3 |
| Wingard, JR | 2 |
| Sandford, GR | 3 |
| Bender, WJ | 1 |
| Saral, R | 2 |
| Radsak, KD | 1 |
| Kelly, C | 1 |
| Van Driel, R | 1 |
| Wilkinson, GW | 1 |
| McVoy, MA | 1 |
| Adler, SP | 1 |
| Hostetler, KY | 1 |
| Kini, GD | 1 |
| Beadle, JR | 1 |
| Aldern, KA | 1 |
| Gardner, MF | 1 |
| Border, R | 1 |
| Kumar, R | 1 |
| Barshak, L | 1 |
| Sridhar, CN | 1 |
| Wheeler, CJ | 1 |
| Richman, DD | 1 |
| Snoeck, R | 3 |
| Andrei, G | 1 |
| De Clercq, E | 3 |
| Boldogh, I | 1 |
| Bui, TK | 1 |
| Szaniszlo, P | 1 |
| Bresnahan, WA | 1 |
| Albrecht, T | 1 |
| Hughes, TK | 1 |
| Timmerman, JJ | 1 |
| Beersma, MF | 1 |
| van Gijlswijk-Janssen, DJ | 1 |
| van Es, LA | 1 |
| van der Woude, FJ | 1 |
| Daha, MR | 1 |
| Giesen, K | 1 |
| Bogner, E | 1 |
| Hirai, K | 1 |
| Maeda, F | 1 |
| Watanabe, Y | 1 |
| Stinski, MF | 2 |
| Isom, HC | 1 |
| Cerrina, J | 1 |
| Le Roy Ladurie, F | 1 |
| Peters, M | 1 |
| Timm, U | 1 |
| Schürmann, D | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Tatarowicz, WA | 1 |
| Lurain, NS | 1 |
| Thompson, KD | 1 |
| Jacobson, MA | 1 |
| Drew, WL | 1 |
| Feinberg, J | 1 |
| O'Donnell, JJ | 1 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Drobyski, WR | 2 |
| Knox, KK | 2 |
| Carrigan, DR | 2 |
| Ash, RC | 1 |
| Sullivan, V | 1 |
| Coen, DM | 1 |
| Smyth, RL | 1 |
| Scott, JP | 1 |
| Borysiewicz, LK | 1 |
| Sharples, LD | 1 |
| Stewart, S | 1 |
| Wreghitt, TG | 1 |
| Gray, JJ | 1 |
| Higenbottam, TW | 1 |
| Wallwork, J | 1 |
| Gerna, G | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Neyts, J | 1 |
| Schols, D | 1 |
| Himpens, B | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Bakker-Woudenberg, IA | 1 |
| Lokerse, AF | 1 |
| ten Kate, M | 1 |
| Youle, M | 1 |
| Chanas, A | 1 |
| Gazzard, B | 1 |
| Manischewitz, JF | 1 |
| Quinnan, GV | 1 |
| Lane, HC | 1 |
| Wittek, AE | 1 |
| Lagneaux, L | 1 |
| Delforge, A | 1 |
| Bron, D | 1 |
| Van der Auwera, P | 1 |
| Stryckmans, P | 1 |
| Balzarini, J | 1 |
| Chiba, S | 1 |
| Eriksson, BF | 1 |
| Schinazi, RF | 1 |
| Ringden, O | 2 |
| Lonnqvist, B | 2 |
| Aschan, J | 1 |
| Sundberg, B | 1 |
| Andersson, J | 1 |
| Akesson-Johansson, A | 2 |
| Brattström, C | 1 |
| Freitas, VR | 1 |
| Fraser-Smith, EB | 1 |
| Matthews, TR | 1 |
| Anders, DG | 2 |
| Kidd, JR | 1 |
| Gibson, W | 3 |
| Lernestedt, JO | 1 |
| Lee, JY | 1 |
| Irmiere, A | 2 |
| Harmenberg, J | 1 |
| Bergman, J | 1 |
| Akerfeldt, S | 1 |
| Lundblad, L | 1 |
| Simons, JW | 1 |
| Staal, SP | 1 |
| Dolin, R | 1 |
| Rudén, U | 1 |
| Gadler, H | 1 |
| La Colla, P | 1 |
| Gelli, G | 1 |
| Mura, L | 1 |
| Landini, MP | 1 |
| Corrias, MV | 1 |
| Pani, A | 1 |
| Marongiu, ME | 1 |
| D'Aquila, RT | 1 |
| Summers, WC | 1 |
| Tyms, AS | 1 |
| Davis, JM | 1 |
| Clarke, JR | 1 |
| Jeffries, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phosphonoacetic acid and Cytomegalovirus
| Article | Year |
|---|---|
[Cytomegalovirus infection in patients after lung transplantation].
Topics: Acyclovir; Antiviral Agents; Blood Transfusion; Cytomegalovirus; Cytomegalovirus Infections; Foscarn | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
3 trials available for phosphonoacetic acid and Cytomegalovirus
| Article | Year |
|---|---|
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
Antiviral chemotherapy and chemoprophylaxis.
Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega | 1985 |
50 other studies available for phosphonoacetic acid and Cytomegalovirus
| Article | Year |
|---|---|
Conditions for cytomegalovirus stimulation of lymphocytes.
Topics: Antibodies, Viral; Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA Replicat | 1981 |
Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.
Topics: Acyclovir; Antiviral Agents; Cell Line; Cytomegalovirus; Drug Evaluation, Preclinical; Drug Synergis | 1982 |
Characterization of human cytomegalovirus-induced DNA polymerase and the associated 3'-to-5', exonuclease.
Topics: Ammonium Sulfate; Aphidicolin; Cytomegalovirus; Diterpenes; DNA-Directed DNA Polymerase; DNA, Single | 1983 |
Inhibition of cytomegalovirus late antigens by phosphonoformate.
Topics: Antigens, Viral; Cell Line; Cytomegalovirus; Cytopathogenic Effect, Viral; DNA-Directed DNA Polymera | 1980 |
Unimpaired histone synthesis in human fibroblasts infected by human cytomegalovirus.
Topics: Cell Line; Cytomegalovirus; DNA; DNA, Viral; Fibroblasts; Histones; Humans; Male; Penis; Phosphonoac | 1980 |
DNA synthesis in chromatin preparations from human fibroblasts infected by cytomegalovirus.
Topics: Cell Line; Cell-Free System; Chromatin; Cytomegalovirus; DNA-Directed DNA Polymerase; DNA, Viral; Fi | 1980 |
Reversible inhibition of cytomegalovirus replication by phosphonoformate.
Topics: Animals; Antigens, Viral; Antiviral Agents; Cells, Cultured; Cricetinae; Cytomegalovirus; Foscarnet; | 1980 |
Dissociation between cellular DNA- and histone synthesis following infection by cytomegalovirus in the presence of phosphonoacetic acid.
Topics: Cytomegalovirus; DNA Replication; DNA, Viral; Fibroblasts; Histones; Humans; Organophosphorus Compou | 1981 |
Human cytomegalovirus-associated DNA polymerase and protein kinase activities.
Topics: Ammonium Sulfate; Cytomegalovirus; DNA; DNA-Directed DNA Polymerase; Humans; Magnesium; Magnesium Ch | 1981 |
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin.
Topics: Animals; Cattle; Cytomegalovirus; Kinetics; Nucleic Acid Synthesis Inhibitors; Organophosphorus Comp | 1982 |
Acyclovir in mouse cytomegalovirus infections.
Topics: Acyclovir; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance; | 1982 |
Inhibition of human cytomegalovirus by trifluorothymidine.
Topics: Acyclovir; Cytomegalovirus; Foscarnet; Humans; Interferon Type I; Lung; Phosphonoacetic Acid; Thymid | 1983 |
Induction of a host-specific chromatin-associated glycopolypeptide by human cytomegalovirus.
Topics: Blood; Cells, Cultured; Chromatin; Cytomegalovirus; Deoxyglucose; DNA Replication; Fibroblasts; Gluc | 1983 |
Disruption of PML-associated nuclear bodies during human cytomegalovirus infection.
Topics: 3T3 Cells; Animals; Antibodies, Viral; Cell Nucleus; Cells, Cultured; Cycloheximide; Cytomegalovirus | 1995 |
Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within the concatemer.
Topics: Aphidicolin; Cells, Cultured; Chromosome Inversion; Cycloheximide; Cytomegalovirus; Deoxyribonucleas | 1994 |
Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line; Cytomegalovirus; DNA, Viral; Foscarnet; Herpesvirus 1, | 1996 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Novel activation of gamma-interferon in nonimmune cells during human cytomegalovirus replication.
Topics: Blotting, Northern; Blotting, Western; Cell Line; Cytomegalovirus; Dactinomycin; DNA Replication; DN | 1997 |
Differential effects of cytomegalovirus infection on complement synthesis by human mesangial cells.
Topics: Blotting, Northern; Cells, Cultured; Complement C2; Complement C4; Complement Factor B; Complement F | 1997 |
Targeting of the gene product encoded by ORF UL56 of human cytomegalovirus into viral replication centers.
Topics: Animals; Cell Nucleus; Cells, Cultured; COS Cells; Cytomegalovirus; DNA Replication; DNA-Binding Pro | 2000 |
Expression of early virus functions in human cytomegalovirus infected HEL cells: effect of ultraviolet light-irradiation of the virus.
Topics: Antigens, Viral; Cell Line; Cell Nucleus; Cytomegalovirus; DNA-Directed DNA Polymerase; DNA, Viral; | 1978 |
Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides.
Topics: Canavanine; Cell Line; Cytomegalovirus; Cytopathogenic Effect, Viral; DNA Replication; DNA, Viral; P | 1978 |
Stimulation of ornithine decarboxylase by human cytomegalovirus.
Topics: Carboxy-Lyases; Cell Line; Cytarabine; Cytomegalovirus; Humans; Immune Sera; Ornithine Decarboxylase | 1979 |
Early virus-specific proteins synthesized in human cytomegalovirus infected cells.
Topics: Animals; Cell Transformation, Viral; Cells, Cultured; Cycloheximide; Cytomegalovirus; DNA, Viral; Fi | 1978 |
A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cytomegalovirus; Drug Resistance, Microbial; | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 1991 |
Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Drug Resistance, Microbial; Fibroblasts; Foscarn | 1991 |
Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Topics: Adolescent; Adult; Antibodies, Viral; Bacterial Infections; Child; Cytomegalovirus; Cytomegalovirus | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.
Topics: Adult; Antiviral Agents; Bone Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Res | 1991 |
Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Drug Carriers; Fibroblasts; Foscarnet; Ganciclov | 1990 |
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.
Topics: Cytomegalovirus; DNA, Viral; Drug Synergism; Foscarnet; Ganciclovir; Phosphonoacetic Acid; Virus Rep | 1990 |
Susceptibility of human herpesvirus 6 to antivirals in vitro.
Topics: Acyclovir; Antiviral Agents; Bromodeoxyuridine; Cells, Cultured; Cytomegalovirus; DNA Replication; G | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome | 1990 |
[Diagnosis and treatment of cytomegalovirus infections].
Topics: Acyclovir; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarn | 1989 |
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Synergism; Fos | 1989 |
Foscarnet prophylaxis in marrow transplant recipients.
Topics: Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Nucleic | 1989 |
Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytomegalovirus; Cytomegalovirus Infections; Drug | 1989 |
Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Dose-Response Relationship, Dr | 1989 |
Immunological characterization of an early cytomegalovirus single-strand DNA-binding protein with similarities to the HSV major DNA-binding protein.
Topics: Cell Compartmentation; Cross Reactions; Cytomegalovirus; DNA-Binding Proteins; DNA, Single-Stranded; | 1987 |
Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly.
Topics: Capsid; Cells, Cultured; Centrifugation, Density Gradient; Cytomegalovirus; DNA, Viral; Electrophore | 1988 |
Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs.
Topics: Acyclovir; Animals; Antigens, Viral; Antiviral Agents; Cell Line; Cytomegalovirus; DNA-Directed DNA | 1988 |
Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir.
Topics: Acyclovir; Cytomegalovirus; DNA Replication; Drug Resistance, Microbial; Genetic Complementation Tes | 1985 |
Activity of the cytomegalovirus genome in the presence of PPi analogs.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Diphosphates; DNA Replication; DNA, Viral; Fosca | 1985 |
Antiherpes activity of 5-(2-bromoethyl)-2'-deoxyuridine.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cell Division; Cell Line; Cytomegalovirus; | 1985 |
Identification and characterization of a major early cytomegalovirus DNA-binding protein.
Topics: Cell Nucleus; Cells, Cultured; Cytomegalovirus; Deoxyribonuclease I; DNA-Binding Proteins; DNA, Sing | 1986 |
Isolation and characterization of phosphonoacetic acid-resistant mutants of human cytomegalovirus.
Topics: Ammonium Sulfate; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Humans; | 1987 |
Synthesis of cytomegalovirus DNA is an antiviral target late in virus growth.
Topics: Acyclovir; Antiviral Agents; Cell Line; Cytomegalovirus; DNA, Viral; Floxuridine; Foscarnet; Gancicl | 1987 |